Baird Cuts Contineum Therapeutics Price Target to $14 From $19
Baird also cut its rating on Contineum Therapeutics to Neutral from Outperform.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.